Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE

Robust monotherapy efficacy in 2L KRAS G12X PDAC: 40% uORR at 16-32 mg QD PAD, 42% uORR at 24-32 mg QD RDE, and 50% uORR at 32 mg QD

Monotherapy generally well-tolerated with mostly low-grade AEs, no DLTs as of DCO, and low rate of dose reductions and no discontinuations due to TRAEs

Preliminary data suggest ERAS-0015 may combine safely with standard-of-care doses of panitumumab with no DLTs as of DCO (N=3) and 1/1 uPR in CRC

Well-behaved PK, with dose-dependent increase in PK exposure up to MAD of 40 mg QD and no exposure plateau observed

Anticipated data disclosure of select ERAS-0015 monotherapy dose expansion and combination dose escalation cohorts narrowed to H1 2027

Conference call and live webcast today at 4:30 PM Eastern Time

SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced positive preliminary Phase 1 dose escalation data for its potentially best-in-class, pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors.

The preliminary data are from Erasca's ongoing AURORAS-1 Phase 1 dose escalation trial in the U.S. and the ongoing JYP0015M101 Phase 1 dose escalation trial in China sponsored by Joyo Pharmatech Co., Ltd. (Joyo), both evaluating ERAS-0015 in patients with RAS-mutant solid tumors.